Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms anti-FLT3 x anti-CD3 BiTE, emirodatamab, FLT3 HLE BITE + [5] |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 1 | China | 09 Dec 2020 | |
Refractory acute myeloid leukemia | Phase 1 | United States | 14 Sep 2018 | |
Refractory acute myeloid leukemia | Phase 1 | Japan | 14 Sep 2018 | |
Refractory acute myeloid leukemia | Phase 1 | Australia | 14 Sep 2018 | |
Refractory acute myeloid leukemia | Phase 1 | Canada | 14 Sep 2018 | |
Refractory acute myeloid leukemia | Phase 1 | Germany | 14 Sep 2018 | |
Relapsing acute myeloid leukemia | Phase 1 | United States | 14 Sep 2018 | |
Relapsing acute myeloid leukemia | Phase 1 | Japan | 14 Sep 2018 | |
Relapsing acute myeloid leukemia | Phase 1 | Australia | 14 Sep 2018 | |
Relapsing acute myeloid leukemia | Phase 1 | Canada | 14 Sep 2018 |